The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-45247-6
Abstract: Fibroblast growth factor receptor (FGFR)−2 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a characteristic pattern… read more here.
Keywords: interaction pattern; pattern lenvatinib; fgfr2 driven; lenvatinib ... See more keywords
Abstract 1968: Discovery of a highly potent and selective FGFR2 inhibitor for FGFR2-driven cancers
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1968
Abstract: Fibroblast growth factor receptor 2 (FGFR2) is a clinically validated target and frequently altered in many solid tumors. The resulting oncogenic driver alterations often drive multiple solid tumors. Therefore, targeting FGFR2 has broad therapeutic potential.… read more here.
Keywords: potent selective; fgfr2 inhibitor; fgfr2 driven; selective fgfr2 ... See more keywords